BMBabak Mamnoon

Babak Mamnoon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Babak Mamnoon has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Li Feng

    Pharmaceutical Sciences Department, North Dakota State University, Fargo, North Dakota 58105, United States

    2 shared publications
  • Sanku Mallik

    Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58108, USA

    2 shared publications
  • Taghi Naserpour Farivar

    Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran

    2 shared publications
  • Ahmad Reza Kamyab

    Dept. of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

    1 shared publication
  • Ali Khamesipour

    Center of Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Dariush Ilghari

    Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran

    1 shared publication

Latest Publications

  • Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors

    by Matthew I. Confeld, Babak Mamnoon, Li Feng, Heather Jensen-Smith, Priyanka Ray, James Froberg, Jiha Kim, Michael A. Hollingsworth, Mohiuddin Quadir, Yongki Choi, et al.

    In pancreatic ductal adenocarcinoma (PDAC), early onset of hypoxia triggers remodeling of the extracellular matrix, epithelial-to-mesenchymal transition, increased cell survival, the formation of cancer stem cells, and drug resistance. Hypoxia in PDAC is also associated with the development of collagen-rich, fibrous extracellular stroma (desmoplasia), resulting in severely impaired drug penetration. To overcome these daunting challenges, we created polymer nanoparticles (polymersomes) that target and penetrate pancreatic tumors, reach the hypoxic niches, undergo rapid structural destabilization, and release the encapsulated drugs. In vitro studies indicated a high cellular uptake of the polymersomes and increased cytotoxicity of the drugs under hypoxia compared to unencapsulated drugs. The polymersomes decreased tumor growth by nearly 250% and significantly increased necrosis within the tumors by 60% in mice compared to untreated controls. We anticipate that these polymer nanoparticles possess a considerable translational potential for delivering drugs to solid hypoxic tumors.


  • Nucleus-Targeted, Echogenic Polymersomes for Delivering a Cancer Stemness Inhibitor to Pancreatic Cancer Cells

    by Fataneh Karandish, Babak Mamnoon, Li Feng, Manas K. Haldar, Lang Xia, Kara N. Gange, Seungyong You, Yongki Choi, Kausik Sarkar, Sanku Mallik

    Chemotherapeutic agents for treating cancers show considerable side effects, toxicity, and drug resistance. To mitigate the problems, we designed nucleus-targeted, echogenic, stimuli-responsive polymeric vesicles (polymersomes) to transport and subsequently release the encapsulated anticancer drugs within the nuclei of pancreatic cancer cells. We synthesized an alkyne-dexamethasone derivative and conjugated it to N3–polyethylene glycol (PEG)–polylactic acid (PLA) copolymer employing the Cu2+ catalyzed “Click” reaction. We prepared polymersomes from the dexamethasone–PEG–PLA conjugate along with a synthesized stimuli-responsive polymer PEG–S–S–PLA. The dexamethasone group dilates the nuclear pore complexes and transports the vesicles to the nuclei. We designed the polymersomes to release the encapsulated drugs in the presence of a high concentration of reducing agents in the nuclei of pancreatic cancer cells. We observed that the nucleus-targeted, stimuli-responsive polymersomes released 70% of encapsulated contents in the nucleus-mimicking environment in 80 min. We encapsulated the cancer stemness inhibitor BBI608 in the vesicles and observed that the BBI608 encapsulated polymersomes reduced the viability of the BxPC3 cells to 43% in three-dimensional spheroid cultures. The polymersomes were prepared following a special protocol so that they scatter ultrasound, allowing imaging by a medical ultrasound scanner. Therefore, these echogenic, targeted, stimuli-responsive, and drug-encapsulated polymersomes have the potential for trackable, targeted carrier of chemotherapeutic drugs to cancer cell nuclei.


  • Open Access

    Quality Control of Widely Used Therapeutic Recombinant Proteins by a Novel Real-Time PCR Approach

    by Babak Mamnoon, Ahmad Reza Kamyab, Dariush Ilghari, Ali Khamesipour, Mohsen Karimi Arzenani, Taghi Naserpour Farivar

    Existence of bacterial host-cell DNA contamination in biopharmaceutical products is a potential risk factor for patients receiving these drugs. Hence, the quantity of contamination must be controlled under the regulatory standards. Although different methods such as hybridization assays have been employed to determine DNA impurities, these methods are labor intensive and rather expensive. In this study, a rapid real-time PCR test was served as a method of choice to quantify the E. coli host- cell DNA contamination in widely used recombinant streptokinase (rSK), and alpha interferon (IFN-α) preparations. A specific primer pair was designed to amplify a sequence inside the E. coli 16S rRNA gene. Serial dilutions of DNA extracted from E. coli host cells, along with DNA extracted from Active Pharmaceutical Ingredients of rSK, and IFN-α samples were subjected to an optimized real-time PCR assay based on SYBR Green chemistry. The test enabled us to detect a small quantity of genomic DNA contamination as low as 0.0002 pg in recombinant protein-based drugs. For the first time, this study showed that DNA contamination in rSK and IFN-α preparation manufactured in Pasteur Institute of Iran is much lower than the safety limit suggested by the US FDA. Real-time PCR is a reliable test for rapid detection of host-cell DNA contamination, which is a major impurity of therapeutic recombinant proteins to keep manufacturers’ minds on refining drugs, and provides consumers with safer biopharmaceuticals.


  • Open Access

    Novel Real Time Polymerase Chain Reaction Approach for Rapid Detection of the Residual Escherichia coli Genomic DNA in Biopharmaceutical Products Establishment of Real Time Polymerase Chain Reaction to Detect Residual gDNA

    by Taghi Naserpour Farivar, Babak Mamnoon, Mohsen Karimi Arzenani, Dariush Ilghari

    Background: Contamination of therapeutic recombinant proteins with residual host cell DNA must be controlled under the regulatory standards. Objectives: The current study established a new rapid, sensitive real time polymerase chain reaction (PCR) approach to measure the reliably of the residual Escherichia coli (E. coli) host cell genomic DNA in the recombinant streptokinase and alfa interferon preparations. Materials and Methods: In this assay, a specific primer pair was utilized to amplify a 115 base pair sequence inside the E. coli 16S rRNA using SYBR Green Chemistry. This method enabled the authors to detect a very small quantity of the residual genomic DNA, as low as 0.8 pg, in the protein-based drugs. This method can, therefore, offer a dependable way to quantitatively analyze the major contaminant of biopharmaceutical products, the host cell DNA, during the manufacturing process. Results: SYBR Green PCR master mix may contain a source of DNA contamination during its manufacturing process. Conclusions: The current study data showed that E. coli host cell DNA contamination in streptokinase and alfa interferon manufactured in the Pasteur institute of Iran is much lower than the safety limits suggested by the FDA. Keywords: Streptokinase; Alfa interferon; Real Time PCR